Article Document Academic Article Information Content Entity Journal Article Continuant Continuant Entity Entity Generically Dependent Continuant 2025-05-09T04:21:55 RDF description of Patch testing with benzophenone-3 and -4: the North American Contact Dermatitis Group experience, 2013-2020 - http://repository.healthpartners.com/individual/document-rn32693 10.1089/derm.2022.29013.ewa Drugs and Drug Therapy Dermatitis 21256 36452 Retrospective Studies Adverse Effects Dermatitis 2 Patch testing with benzophenone-3 and -4: the North American Contact Dermatitis Group experience, 2013-2020 <p>Background: Benzophenone (BZP)-3 and BZP-4 are ultraviolet (UV) absorbers used in sunscreens and personal care products (PCPs) and may cause allergic contact dermatitis. Objective: To characterize positive patch test reactions to BZP-3 (10% in petrolatum [pet]) and BZP-4 (2% pet) in a screening allergen series. Methods: Retrospective analysis of patients tested to BZP-3 and BZP-4 was conducted by the North American Contact Dermatitis Group from 2013 to 2020. Results: Of 19,618 patients patch tested to BZP-3 and BZP-4, 103 (0.5%) and 323 (1.6%) had positive reactions, respectively: 413 (2.1%) reacted to at least 1 BZP (BZP-positive patient). As compared with BZP-negative patients, BZP-positive patients were significantly more likely to have a history of hay fever (39.3% vs 33.4%, P�=�0.0134), history of atopic dermatitis (39.8% vs 30.7%, P�=�0.0001), and facial involvement (37.4% vs 32.2%, P�=�0.0272). Most reactions were currently clinically relevant (BZP-3: 90.4%; BZP-4: 65.8%). Common identified sources included PCPs and sunscreens. Coreactivity between BZP-3 and BZP-4 was low: 13.5% (14/104) of BZP-3-positive patients were allergic to BZP-4 and 4.3% (14/322) of BZP-4-positive patients were allergic to BZP-3. Conclusions: Eight-year prevalence of BZP positivity was 2.1%. Reactions were frequently clinically relevant and linked to PCPs and sunscreens.<p> document-rn32693 34 public 2023-06-30T21:52:02.627-05:00